A5102719970- Cardiovascular Function and Risk Factors
- Cardiomyopathy and Myosin Studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Effects of Exercise
- Advanced MRI Techniques and Applications
- Cardiac pacing and defibrillation studies
- Cardiac electrophysiology and arrhythmias
- Congenital Heart Disease Studies
- Advanced battery technologies research
- Cardiac Valve Diseases and Treatments
- Pancreatic and Hepatic Oncology Research
- Ultrasound Imaging and Elastography
- Sports injuries and prevention
- Cardiovascular Health and Disease Prevention
- Elasticity and Material Modeling
- Cardiac Structural Anomalies and Repair
- Wireless Body Area Networks
- Wireless Power Transfer Systems
- Vitamin D Research Studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Smart Agriculture and AI
- Voice and Speech Disorders
- Trypanosoma species research and implications
- Cardiovascular and Diving-Related Complications
- Cardiac Fibrosis and Remodeling
University of California, San Francisco
2019-2025
Rajagiri Hospital
2024
Oregon Health & Science University
2024
University of Michigan
2024
University of San Francisco
2023
St. Elizabeth Youngstown Hospital
2023
Bon Secours Mercy Health
2023
Tufts Medical Center
2022
University of Pennsylvania
2022
Meridian Institute
2020
In nonobstructive hypertrophic cardiomyopathy (nHCM), there are no approved medical therapies. Impaired myocardial energetics is a potential cause of symptoms and exercise limitation. Ninerafaxstat, novel cardiac mitotrope, enhances energetics. To evaluate the safety efficacy ninerafaxstat in nHCM. Patients with HCM left ventricular (LV) outflow gradient <30 mmHg, ejection fraction ≥50% peak VO2 <80% predicted, were randomized to 200 mg BID or placebo (1:1) for 12 weeks. Primary endpoint was...
Background This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). Methods Patients symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤30 mmHg, left ejection fraction [LVEF] ≥60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] >300 pg/mL) received 5–20 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks. Results 41 were enrolled (mean ± SD age 56 16...
Long-term safety and efficacy of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) are unknown. MAVA-LTE (NCT03723655) is an ongoing, 5-year, open-label extension study designed to evaluate the long-term effects mavacamten.
Background: Assessment of left ventricular (LV) filling pressure is among the important components a comprehensive echocardiographic report. Previous studies noted wide limits agreement using 2009 American Society Echocardiography/European Association Echocardiography guidelines, but reproducibility 2016 guidelines update in estimating LV unknown. Methods: Echocardiographic and hemodynamic data were obtained from 50 patients undergoing cardiac catheterization for clinical indications....
The role of biomarker testing in the management obstructive hypertrophic cardiomyopathy (oHCM) is not well defined. This pre-specified analysis SEQUOIA-HCM (NCT05186818) sought to define associations between clinical characteristics and baseline concentrations N-terminal pro-B-type natriuretic peptide (NT-proBNP) high-sensitivity cardiac troponin I (hs-cTnI), evaluate effect treatment with aficamten on concentrations.
Importance Impaired exercise capacity is a cardinal manifestation of obstructive hypertrophic cardiomyopathy (HCM). The Phase 3 Trial to Evaluate the Efficacy and Safety Aficamten Compared Placebo in Adults With Symptomatic Obstructive HCM (SEQUOIA-HCM) pivotal study characterizing treatment effect aficamten, next-in-class cardiac myosin inhibitor, on comprehensive set performance clinical measures. Objective To evaluate aficamten using cardiopulmonary testing with novel integrated measure...
Abstract Cellular mechanisms causing cardiac hypertrophy are currently under intense investigation. We report a novel finding in the TGFβ inducible early gene (TIEG) null mouse implicating TIEG1 hypertrophy. The TIEG −/− knock‐out was studied. Male mice age 4–16 months were characterized (N = 86 total) using echocardiography, transcript profiling by microarray, and immunohistochemistry localized upregulated genes for determination of cellular mechanism. female 40) did not develop or...
Abstract Hypertrophic cardiomyopathy (HCM) is a genetic heart disease that associated with many pathological features, such as reduction in global longitudinal strain (GLS), myofiber disarray and hypertrophy. The effects of these features on left ventricle (LV) function are, however, not clear two phenotypes HCM, namely, obstructive non-obstructive. To address this issue, we developed patient-specific computational models the LV using clinical measurements from 2 female HCM patients control...
Abstract Background Incidence of sudden cardiac death (SCD) is 1%/year in cohorts with hypertrophic cardiomyopathy (HCM), but this estimate presumes arrhythmic cause and misses occult cases dying before diagnosis. Methods POST SCD (POstmortem Systematic InvesTigation Sudden Cardiac Death) a prospective cohort study using autopsy, clinical records, toxicology to adjudicate or non-arrhythmic causes among presumed SCDs (pSCDs) meeting WHO criteria aged 0-90 years San Francisco County. We...
Strain echocardiography (SE) provides the rate and extent of myocardial segment shortening lengthening. Thus we hypothesized that SE will noninvasively provide estimates velocity (SV) length change (δ L). We compared SE-derived strain (SR) (ϵ) to force/length transducer-derived SV percent δ L in isolated muscle strips at multiple load levels under varying conditions. Electrically stimulated contractions left ventricular ( n = 20) were simultaneously recorded with a transducer (to measure L)...
Background— Onset of myocardial relaxation is highly energy dependent. Perfusion and therefore substrate delivery are predominantly reduced in the subendocardial myocardium early stages progressive ischemia. We hypothesized that delayed onset diastolic thinning will functionally identify regionally hypoperfused resting myocardium. Methods Results— Progressive left anterior descending coronary artery stenosis was induced by an ameroid occluder maintained for 1 or 2 weeks (end point) 12 dogs....